Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Black Diamond Therapeutics Inc BDTX

Healthcare Biotechnology
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant... see more

Current News (NDAQ:BDTX)

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

GlobeNewswire December 3, 2025

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

GlobeNewswire December 2, 2025

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 6, 2025

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2025

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2025

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2025

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2025

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire March 31, 2025

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

GlobeNewswire March 19, 2025
View More News ››

Opinion & Analysis (NDAQ:BDTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BDTX)

Buy buddy buy because it's taking off this morning.

Otherwise you guys will be missing out on this stock today and it is going up big-time
coolfooldumbguy - March 19, 2025

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX): Pioneering P

http://beyondspx.com/2024/08/01/black-diamond-therapeutics-inc-nasdaqbdtx-pioneering-precision-oncology-with-innovative-masterkey...
MikeTester - August 1, 2024

Nice

:)
Cobalt - June 27, 2023

Wow! Not a Great looking stock chart for an investor

I wonder why there's been no financial corporate reporting listed on SH for BDTX?  Caveat Emptor, Barnsy
barnsy - March 4, 2021
View more Bullboard ››

Metal Quest Mining Inc

Metal Quest Mining Inc

MetalQuest Mining Inc., an exploration stage company, engages in the acquisition, exploration, and development mineral ...
View More »

Podcasts